EcoR1 Capital, LLC Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001587114
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2025 · 30 positions · Total reported value $2.08B · Top-10 concentration 80.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 55.3% · 9 new · 5 cut · 7 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +32.8% · vs SPY +18.0% · Prev Value $2.12B — last quarter positions weighted by this quarter price moves · ranking
In its Q3 2025 13F filing, EcoR1 Capital, LLC disclosed 30 equity positions with a combined reported value of $2.08B. The filing implies a focused portfolio: its ten largest positions account for 80.6% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2025 were ZYME ($392.33M), ANAB ($241.29M), QURE ($232.84M). By sector, the heaviest allocations are Health Care 81.8%, Other 18.2%. Versus the prior quarter, allocation shifted toward Health Care (+15.4pp) and away from Other (-15.0pp).
Versus the prior quarter, EcoR1 Capital, LLC opened 9 new positions, trimmed 5 and fully exited 7, a turnover rate of 55.3% of positions. The portfolio's overlap with the prior quarter was 57% of names.
The largest new positions opened in Q3 2025 were BBOT ($32.69M), AQST ($14.67M), CNTA ($13.34M).
Of the 7 positions fully exited versus the prior quarter, the largest were ITOS ($106.57M), JANX ($33.95M), AKRO ($23.48M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2025)
- BBOT BridgeBio Oncology Therapeutic Inc · $32.69M
- AQST AQUESTIVE THERAPEUTICS INC · $14.67M
- CNTA CENTESSA PHARMACEUTICALS PLC · $13.34M
- PRME PRIME MEDICINE INC · $8.55M
- PEPG PEPGEN INC · $3.70M
- CMPS COMPASS PATHWAYS PLC · $1.52M
Fully Exited (vs previous quarter)
- ITOS ITEOS THERAPEUTICS INC · prev qtr: $106.57M
- JANX JANUX THERAPEUTICS INC · prev qtr: $33.95M
- AKRO AKERO THERAPEUTICS INC · prev qtr: $23.48M
- VRNA VERONA PHARMA PLC · prev qtr: $18.92M
- TECX TECTONIC THERAPEUTIC INCORPORATED · prev qtr: $18.58M
- PCRX PACIRA BIOSCIENCES INC · prev qtr: $10.93M
- REPL REPLIMUNE GROUP INC · prev qtr: $7.90M
- ADAPY ADAPTIMMUNE THERAPEUTICS PLC · prev qtr: $6.57M
Insider Transactions (Form 4)
Latest EcoR1 Capital, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-07 | Buy | Atara Biotherapeutics, Inc. | 507,407 | $9.35 | SEC filing |
| 2026-04-20 | Sell | First Tracks Biotherapeutics, Inc. | 4,705,575 | $13.81 | SEC filing |
Fund Profile
EcoR1 Capital, LLC, based in San Francisco, CA, United States, files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 31 positions worth $1.95B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: SAN FRANCISCO, CA, United States
- SEC registration: 801-100470 (status: Approved), registered 2015-07-02
- Regulatory AUM (Form ADV): $3.42B as of 2026-03-30
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 3 private funds, of which 2 hedge funds
Portfolio Structure
- 31 positions · $1.95B reported value (Q2 2026)
- Top 10 holdings = 87.7% of reported value
- Largest position: ZYME (ZYMEWORKS INC) at 30.8%
- Average position size: $62.85M
Sector Tilt
- Health Care 97.3%
- Financials 0.1%
- (classified holdings cover 97% of value)
Quarterly Activity
- Q2 2026: 9 new, 2 added, 5 reduced, 7 exited
- 15 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
22.97M | $392.33M | 18.83% | Hold | |
| 2 |
|
7.88M | $241.29M | 11.58% | Hold | |
| 3 |
|
3.99M | $232.84M | 11.17% | Add | |
| 4 |
|
1.71M | $224.91M | 10.79% | Hold | |
| 5 |
|
4.29M | $178.60M | 8.57% | Hold | |
| 6 |
|
1.39M | $90.04M | 4.32% | Hold | |
| 7 |
|
10.63M | $89.30M | 4.29% | Hold | |
| 8 |
|
6.73M | $80.74M | 3.87% | Add | |
| 9 |
|
3.45M | $78.01M | 3.74% | Reduce | |
| 10 |
|
6.14M | $72.08M | 3.46% | Hold | |
| 11 |
|
1.67M | $57.75M | 2.77% | Add | |
| 12 |
|
4.08M | $47.77M | 2.29% | Hold | |
| 13 |
|
2.03M | $44.12M | 2.12% | Hold | |
| 14 |
|
2.12M | $37.16M | 1.78% | Add | |
| 15 |
|
75.00K | $34.40M | 1.65% | Hold | |
| 16 |
|
765.00K | $33.33M | 1.60% | Add | |
| 17 |
|
2.82M | $32.69M | 1.57% | New | |
| 18 |
|
1.27M | $22.03M | 1.06% | Hold | |
| 19 |
|
500.00K | $15.00M | 0.72% | Hold | |
| 20 |
|
2.62M | $14.67M | 0.70% | New | |
| 21 |
|
271.53K | $14.21M | 0.68% | Hold | |
| 22 |
|
550.00K | $13.34M | 0.64% | New | |
| 23 |
|
1.54M | $8.55M | 0.41% | New | |
| 24 |
|
573.18K | $8.21M | 0.39% | Hold | |
| 25 |
|
872.50K | $7.72M | 0.37% | Reduce | |
| 26 |
|
800.00K | $3.70M | 0.18% | New | |
| 27 |
|
963.33K | $3.56M | 0.17% | Hold | |
| 28 |
|
670.30K | $3.13M | 0.15% | Reduce | |
| 29 |
|
265.14K | $1.52M | 0.07% | New | |
| 30 |
|
66.67K | $859.31K | 0.04% | Hold | |
FAQ
What did EcoR1 Capital, LLC buy in 2025-Q3?
In its 2025-Q3 13F filing, EcoR1 Capital, LLC reported 30 equity positions worth $2.08B in aggregate; its largest disclosed positions were ZYME ($392.33M), ANAB ($241.29M), QURE ($232.84M).
How large is EcoR1 Capital, LLC's portfolio?
EcoR1 Capital, LLC reported $2.08B of long equity holdings across 30 positions as of 2025-Q3. Top-10 holdings account for 80.6% of reported value.
What is EcoR1 Capital, LLC's investment style?
HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.